Open AccessSuccessful rechallenge with cisplatin following cisplatin induced ischemic cerebrovascular accident in a patient with small cell lung cancer
Author(s) -
Rashid Farah,
Omar Nabil E.,
Aaekl Hassan,
Al Homsi Ussama,
Shablak Alaaeldin
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.6469
Subject(s) - medicine , cisplatin , nephrotoxicity , lung cancer , chemotherapy , regimen , oncology , adverse effect , toxicity
Abstract Cisplatin is a widely used platinum‐based chemotherapy agent. Its common adverse effects are neuropathy, nephrotoxicity, electrolyte abnormality, and rarely causing thrombotic vascular toxicity. We present a patient known to have small‐cell lung cancer who developed ischemic cerebrovascular accident (CVA) after receiving chemotherapy regimen including cisplatin.